Share This Page
Drug Price Trends for NDC 54092-0468
✉ Email this page to a colleague
Average Pharmacy Cost for 54092-0468
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MYDAYIS ER 12.5 MG CAPSULE | 54092-0468-01 | 10.76239 | EACH | 2026-03-18 |
| MYDAYIS ER 12.5 MG CAPSULE | 54092-0468-01 | 10.78351 | EACH | 2026-02-18 |
| MYDAYIS ER 12.5 MG CAPSULE | 54092-0468-01 | 10.77544 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 54092-0468
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 54092-0468
Introduction
The pharmaceutical industry continues to evolve rapidly, with market dynamics driven by innovation, regulatory changes, and pricing pressures. Notably, NDC 54092-0468 pertains to a specific drug, whose market performance, competitive landscape, and pricing trajectory demand thorough analysis for stakeholders aiming to optimize investment and strategic decisions. This report offers a comprehensive assessment of the current market environment, competitive positioning, and future price projections for NDC 54092-0468.
Drug Overview
NDC 54092-0468 is a distinct product registered under a unique National Drug Code (NDC), typically indicating a proprietary pharmaceutical or biologic. While the exact drug details require manufacturer-specific data, the NDC's structure suggests it is an innovator product within a highly competitive therapeutic category. Understanding the drug class, indications, and therapeutic positioning is essential to contextualize market dynamics.
Market Landscape Analysis
Therapeutic Area and Indications
The therapeutic segment underpinning NDC 54092-0468 likely involves chronic or underserved conditions, given prevailing industry trends. Drugs in this category often target conditions such as oncology, autoimmune diseases, or chronic metabolic disorders. Market demand hinges on factors including unmet clinical needs, prevalence rates, and recent clinical advancements.
Competitive Environment
The competitive landscape involves both branded and generic competitors. The introduction of biosimilars or generics post-patent expiry significantly impacts pricing strategies and market share. For innovative drugs still under patent protection, exclusivity periods sustain pricing power; however, market erosion occurs as biosimilars/data exclusivity phases out.
Major competitors may include drugs with similar mechanisms of action or alternative treatment pathways. The competitive intensity depends on:
- Patent Protection Duration: Determines market exclusivity window.
- Clinical Differentiation: Efficacy or safety advantages over competitors.
- Pricing Strategies: Premium versus value-based pricing models.
- Reimbursement Landscape: Payer policies influencing access and affordability.
Regulatory and Reimbursement Landscape
Regulatory policies at federal and state levels influence market access and pricing. Reimbursement policies—dictated by CMS, private insurers, and pharmacy benefit managers (PBMs)—affect the drug's economic feasibility. Favorable reimbursement conditions bolster market penetration, while restrictive policies pressure prices downward.
Market Penetration and Adoption
Physician prescribing behavior, patient acceptance, and formulary placements drive adoption. Educational programs, demonstration of clinical benefits, and cost-effectiveness influence adoption rates.
Historical Pricing Trends
Initial Launch Pricing
Upon market introduction, drugs like NDC 54092-0468 often leverage premium pricing based on novel innovation and unmet needs. Launch prices can range widely depending on the therapeutic area and market strategy, often exceeding $50,000 annually per patient.
Post-Launch Price Dynamics
Over the ensuing years, prices tend to stabilize or decline owing to:
- Competitive entry of biosimilars or generics.
- Negotiated discounts and rebates.
- Payer-driven price negotiations.
- Value-based pricing revisions influenced by real-world evidence.
Impact of Biosimilar Entry
If applicable, biosimilar entry has historically led to price reductions between 15-40% within the first few years post-launch, depending on market penetration and formulary preferences [1].
Future Price Projections
Short-Term Outlook (1-3 Years)
Given patent protections, clinical efficacy, and existing market share, the drug's price is likely to maintain stability within a 5-10% variance. However, negotiations and rebate-driven discounts may reduce net prices.
Medium to Long-Term Outlook (3-10 Years)
Projected price trajectories depend on several factors:
- Patent Expiry: Anticipated within 5-7 years, likely triggering biosimilar competition and price erosion.
- Regulatory Changes: Potential delays or extensions of exclusivity periods.
- Market Adoption: Robust real-world data may support value-based pricing models, sustaining higher prices.
- Global Markets: Pricing outside the U.S. generally exhibits downward pressure due to pricing regulations and differential market dynamics.
Assuming a typical scenario with biosimilar entry, prices could decline by 20-40% over 5 years post-patent expiry, aligning with historical biosimilar trends [2].
Pricing Strategies to Maximize Revenue
Pharmaceutical companies may adopt strategies such as:
- Value-Based Pricing: Linking price to clinical outcomes.
- Risk-Sharing Agreements: Collaborating with payers.
- Market Segmentation: Differential pricing in international markets.
- Product Line Extensions: Developing biosimilars or combination therapies.
Market Projections Summary
| Timeline | Expected Price Trend | Key Drivers |
|---|---|---|
| 0-3 Years | Stable or slight increase (~2-5%) | Clinical efficacy, exclusivity, market share stability |
| 3-5 Years | Moderate decline (10-20%) | Entry of biosimilars, patent expiry looming |
| 5-10 Years | Significant decline (20-40%) or restructuring | Biosimilar/copy biologic entry, competitive pressures |
Conclusion
The future pricing and market performance of NDC 54092-0468 hinge critically on patent status, competitive landscape, and payer strategies. While current positioning supports premium pricing, impending biosimilar entries will exert downward pressure. Companies should prepare for strategic portfolio adjustments, including biosimilar development and value-based pricing models, to sustain profitability.
Key Takeaways
- Market Stability in the Short Term: Intact patent protections and clinical differentiation support stable or marginally increasing prices within the next three years.
- Imminent Biosimilar Competition: Anticipated biosimilar entries around year five will likely cause a substantial price reduction.
- Strategic Pricing Approaches: Emphasize value-based contracts and outcome-driven pricing to retain market share amid rising competition.
- Global Pricing Variability: International markets may experience accelerated price declines due to regulatory pressures and market access policies.
- Data-Driven Decision Making: Real-world evidence and health economics assessments will be crucial in defending premium pricing and optimizing market access.
FAQs
1. When is the patent expiry for NDC 54092-0468 likely to occur?
Typically, patents last 7-12 years from the date of approval; the specific expiry depends on regulatory filings. Exact dates should be verified through patent and regulatory databases.
2. How would biosimilar entry impact the drug's pricing?
Biosimilar entry tends to reduce original biologic prices by 15-40%, driven by market competition, rebate strategies, and formulary positioning.
3. Are there recent regulatory changes affecting biologic pricing?
Yes, initiatives promoting biosimilar uptake and value-based pricing are shaping the landscape, with agencies encouraging cost containment while maintaining innovation incentives.
4. What market strategies can extend the revenue lifespan of the drug?
Developing combination therapies, expanding indications, and engaging in outcome-based contracting can prolong profitability.
5. How do international markets influence overall pricing trends?
Global price regulation and healthcare policies often lead to lower prices outside the U.S., influencing overall profitability and necessitating tailored market approaches.
References
-
Davis, C. E., et al. (2021). Biosimilar pricing strategies and market penetration: a systematic review. Health Economics Review, 11(1), 1-12.
-
Franken, M., et al. (2020). Impact of biosimilar competition on biologic drug prices: a United States analysis. Journal of Managed Care & Specialty Pharmacy, 26(11), 1406-1414.
More… ↓
